The most at-risk areas are in poorer industrial parts of Houston. Getty Images

A group of researchers from the University of Texas and the University of Houston have created a mapping tool for identifying which parts of the greater Houston area are at the greatest risk from COVID-19.

"The map offers a comparative look at vulnerabilities across Harris County, and could help policy makers determine how to allocate coronavirus tests and health and safety resources," says Amin Kiaghadi, a research associate at UT's Oden Institute for Computational Engineering & Sciences and postdoctoral fellow at the University of Houston, in a news release.

The study, which is posted on MedRxiv, looked into access to health care, pollutant exposure, and medical insurance coverage. Kiaghadi and two UH professors, Hanadi Rifai and Winston Liaw, concluded that the areas most at risk were in the east and northeastern parts of town — especially industrial areas and high-traffic waterways.

The research showed that the highest risk areas were identified as poorer communities, like the area near the Houston Ship Channel. Consequently, populations with lower risk are in the far west areas of Harris County, which tend to be considered nicer areas. According to the release, around 17 percent of the county's population falls into a risk category.

"I'm really interested to see how decision makers look at these maps," Kiaghadi continues. "They can say 'this specific area is vulnerable to many different things—people living there have lower income, they have or they don't have access to the medical care— and that can change the way that they distribute the resources."

Kiaghadi usually focuses on floodwaters spread contamination, and he postulates that his work in this field had an application within the pandemic.

"We believe that if you're exposed to some chemicals for a long time or you were living in an area with bad air quality, that can affect your immune system long term and then make you more vulnerable to a disease like COVID-19," Kiaghadi says. "So we decided to take a new approach here and show that these factors should be considered."

Based on census data, the map is divided up into 786 polygons and looks into 46 different variables in five categories:

  1. People with limited access to hospitals and medical care.
  2. People with underlying medical conditions.
  3. People with exposures to environmental pollutants.
  4. People in areas vulnerable to natural disasters and flooding.
  5. People with specific lifestyle factors, like obesity, drinking and smoking.

According to the release, the researchers formulated the map within just a couple weeks.

"We already had a lot of knowledge and experience working with this sociodemographic data, and population vulnerability to the flaws in the environment and exposure," Kiaghadi says. "So we felt like, this is totally related to our research, so why not explore what it means?"

The map is broken down by 786 census tracts. Graphic via utexas.edu

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."